BIOLIFE SOLUTIONS INC (BLFS) Form 10-Q — Aug 6, 2026

$BLFSForm 10-QFiled Aug 6, 2026, 4:22 PM ET0001628280-26-054355Original filing

BioLife Solutions' Q2 2026 10-Q shows revenue of $28.5 million, up 21% year over year, with the company swinging to operating income of $1.7 million from a $16.1 million loss a year earlier. Net income of $45.1 million ($0.92 basic EPS) was driven primarily by a one-time $42.3 million income tax benefit tied to recognition of a $42.2 million deferred tax asset. The filing confirms the definitive merger agreement signed July 21, 2026 under which Repligen will acquire all outstanding BioLife shares for $11.25 in cash plus 0.1442 Repligen shares per share, with closing expected in the fourth quarter of 2026 pending stockholder approval, HSR clearance, and S-4 effectiveness.

Key figures

Eps: $0.92 basic / $0.91 diluted (Q2 2026) vs. $(0.33) basic (Q2 2025)
Revenue: $28.5 million (Q2 2026, +21% YoY); $56.0 million (H1 2026, +23% YoY)
Net Income: $45.1 million (Q2 2026); $46.3 million (H1 2026) — includes $42.3 million income tax benefit
Total Debt: $0 — Term Loan repaid in full June 1, 2026 (was $5.0 million at Dec 31, 2025)
Revenue Yoy: 21% (Q2 2026); 23% (H1 2026)
Total Assets: $447.5 million
Cash Position: $113.1 million in cash, cash equivalents, and available-for-sale securities; $24.0 million cash and equivalents at June 30, 2026
Shares Outstanding: 48906704
Goodwill: $208.6 million
Outside date: January 31, 2027 (subject to extensions)
Expected close: Q4 2026
Termination fee: $59.0 million
Deferred tax assets: $42.2 million recognized
Shareholders equity: $420.0 million
Gross margin q2 2026: 64% (down ~1 pt YoY)
Merger cash component: $11.25 per share
Merger stock component: 0.1442 Repligen shares per BioLife share
Operating income q2 2026: $1.7 million vs. $(16.1) million (Q2 2025)
Savsu divestiture net gain: $10.3 million (Q4 2025)
Operating cash flow h1 2026: $5.9 million
Purchase obligations short term: $16.3 million

Price after filing

1 day: +3.9%7 days: +8.3%30 days: +8.4%

Close on the filing date to close N calendar days later (from $32.52). Historical, not a forecast.

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.